Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail.

May 10, 2024

Consolidated Financial Results
for the Fiscal Year Ended March 31, 2024
(Under Japanese GAAP)
Company name:
Takara Bio Inc.
Listing:
Tokyo Stock Exchange
Securities code:
4974
URL:
https://www.takara-bio.co.jp
Representative:
Koichi Nakao, President & CEO
Inquiries:
Takuya Kakemi, Executive Officer, in charge of PR & IR Department
Telephone:+81-77-565-6970
Scheduled date of annual general meeting of shareholders:June 21, 2024
Scheduled date to commence dividend payments:
June 24, 2024
Scheduled date to file annual securities report:
June 27, 2024
Preparation of supplementary material on financial results:
Yes
Holding of financial results briefing:
Yes(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2024(from April 1, 2023 to March 31,
2024)(1) Consolidated operating results(Percentages indicate year-on-year changes.)

Net sales
Fiscal year ended

Operating profit

Millions of yen%

Mar. 31, 2024

43,505Mar. 31, 2023

78,142

Note: Comprehensive income

Millions of yen%(44.3)

3,003

15.4

20,541Millions of yen%(85.4)

3,405(28.9)

20,682For the fiscal year ended Mar. 31, 2024:
For the fiscal year ended Mar. 31, 2023:

Net income
per share
Fiscal year ended

Fully Diluted net
income per share
Yen

Profit attributable toowners of parent

Ordinary profit

Millions of yen%(83.5)

1,480(90.8)(27.3)

16,012(19.3)¥4,387 million¥20,363 million

Return on equity

Yen(78.5%)(14.0%)

Ratio of ordinary
profit to total assets

Ratio of operating
profit to net sales

%

%

%

Mar. 31, 2024

12.30

-

1.3

2.7

6.9

Mar. 31, 2023

132.97

-

15.4

16.9

26.3

Reference:

Share of profit (loss) of entities accounted for using equity method
For the fiscal year ended Mar. 31, 2024:¥- million
For the fiscal year ended Mar. 31, 2023:¥- million(2) Consolidated financial position
Total assets
As of

Net assets

Millions of yen

Equity ratio

Net assets per share

Millions of yen%

YenMar. 31, 2024

121,252

111,78492.0

926.00Mar. 31, 2023

129,202112,45486.9

931.93

Reference:

EquityAs of Mar. 31, 2024:
As of Mar. 31. 2023:¥111,505 million¥112,219 million

(3) Consolidated cash flows
Cash flows fromoperating activities
Fiscal year ended

Cash flows frominvesting activities

Cash and cash
equivalents at end of
periodCash flows fromfinancing activities

Millions of yen

Millions of yen

Millions of yen

Millions of yen

Mar. 31, 2024

1,711

(13,043)(5,233)33,171Mar. 31, 2023

36,897(6,693)(4,119)49,058

2. Cash dividends
Annual dividends per share
First
SecondThird
quarter-end quarter-end quarter-end
Yen
Fiscal year ended
Mar. 31, 2023
Fiscal year ended
Mar. 31, 2024
Fiscal year ending
Mar. 31, 2025
(Forecast)

Yen

Fiscalyear-end

Yen

Total

Yen

Ratio of
Payout ratio dividends to(Consolidated) net assets(Consolidated)

Total cash
dividends(Total)Yen Millions of yen

%

%

-

0.00

-

42.00

42.00

5,057

31.6

4.9

-

0.00

-

17.00

17.00

2,047

138.2

1.8

-

0.00

-

17.00

17.00

60.2

3. Consolidated financial forecasts for the fiscal year ending March 31, 2025 (April. 1, 2024 – March. 31, 2025)(Percentages indicate year-on-year changes.)

Net sales
Millions of yen

Operating profit%

Millions ofyen%

150 (89.4)

250
5,200

% Millions of yen

Second quarter(cumulative)

20,200

5.7

Full year

48,90012.4

Net income
attributable toowners of the parent

Ordinary profit

5,000

66.5

Millions ofyen

Net income per
share

%

Yen

(84.4)

100 (90.8)

0.83

52.7

3,400 129.6

28.24* Notes(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change
in scope of consolidation): None
Newly included: - companies (Company name)
Excluded:- companies (Company name)(2) Changes in accounting policies, changes in accounting estimates, and restatement(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None(ii) Changes in accounting policies due to other reasons: None(iii) Changes in accounting estimates: None(iv) Restatement: None
(3) Number of issued shares (common shares)(i)

Total number of issued shares at the end of the period (including treasury shares)
As of Mar. 31, 2024
As of Mar. 31, 2023

120,415,600 shares
120,415,600 shares(ii) Number of treasury shares at the end of the period
As of Mar. 31, 2024
As of Mar. 31, 2023

- shares- shares(iii) Average number of shares outstanding during the period
Fiscal year ended Mar. 31, 2024
Fiscal year ended Mar. 31, 2023

120,415,600 shares
120,415,600 shares(Reference) Summary of Non-consolidated Financial Results
1. Non-consolidated results for the year ended March 31, 2024 (April 1, 2023 – March 31, 2024)(1) Non-consolidated Results of Operations
Year ended
Year ended
Mar. 31, 2024
Mar. 31, 2023
(Millions of yen)(%) (Millions of yen)(%)
Net sales
27,043(52.8)
57,28013.7
Operating profit
1,546(89.4)
14,553(33.6)
Ordinary profit
3,853(77.9)
17,444(30.4)Net income
2,899(79.7)
14,313(22.6)Net income per share (in yen)
24.8
118.87
Fully diluted net income per share (in yen)
(2) Non-consolidated Financial Position
Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

As of Mar. 31, 2024
(Millions of yen)

100,320
94,38594.1
783.83
94,385

As of Mar 31, 2023
(Millions of yen)

108,607
96,54488.9
801.7696,544<Reasons for the difference from the results of the previous fiscal year for the non-consolidated results>
In the fiscal year under review, we experienced a decrease in net sales due to a decrease in sales of testing-related
products for the new Coronavirus and a slump in the life science research market affected by the economic
downturn overseas. As a result, there was a difference between the actual value for the previous fiscal year and theactual value for the current fiscal year.

* Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.
* Proper use of earnings forecasts, and other special matters
Forward-looking statements contained in this document are determined by the Takara Bio Inc. (the “Company”)
based on information currently available to the Company and include a number of uncertainties. Actual results
could differ from these forecasts due to changes in conditions that occur in the future. For information regarding
the above, please refer to “1. Overview of Financial Results for the year ended March 31, 2024, (4) Future Outlook
on page 3 of the attached document.
The Company will hold a briefing for institutional investors and analysts on Tuesday, May 14, 2024. The material
handed out at this briefing and a review of questions and answers will be posted on our website after the briefing.

Contents of the attached document
1. Overview of Financial Results for the year ended March 31, 2024.............................................................
(1) Overview of Financial Results.................................................................................................................
(2) Overview of Financial Position...............................................................................................................
(3) Overview of Cash Flows.........................................................................................................................
(4) Future Outlook.........................................................................................................................................
2. Basic Concept on Selection of Accounting Standards.................................................................................
3. Consolidated Financial Statements and Primary Notes................................................................................
(1) Consolidated Balance Sheets...................................................................................................................
(2) Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income...
(Consolidated Statements of Profit or Loss)........................................................................................
(Consolidated Statements of Comprehensive Income)........................................................................
(3) Consolidated Statements of Change in Net Assets..................................................................................
(4) Consolidated Statements of Cash Flows.................................................................................................
(5) Notes to Consolidated Financial Statements...........................................................................................
(Notes on Premise of Going Concern)...................................................................................................
(Significant Accounting Estimates)........................................................................................................
(Changes in Presentation Method)..........................................................................................................
(Segment Information)...........................................................................................................................
(Per-Share Information)..........................................................................................................................
(Significant Subsequent Events)............................................................................................................
4. Supplementary Information..........................................................................................................................
(1) Trends in Key Indicators for Business Management...............................................................................
(2) Comparative Consolidated Statement of Income....................................................................................
(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts.................................

-1-

2
2
2
2
3
3
4
4
6
6
7
8
9
10
10
10
10
10
10
11
12
12
13
14

1. Overview of Financial Results for the year ended March 31, 2024
(1) Overview of Financial Results
The outlook for the global economy in the fiscal year under review is uncertain due to prolonged inflation, a
slowdown in the Chinese economy, and Russia’s invasion of Ukraine.
Under these circumstances, in the Long-Term Management Plan 2026 for the six-year period ending March 31,
2026, and the Medium-Term Management Plan 2026 for the three-year period ending March 31, 2026, we havepromoted the development of basic biotechnology-based biologics development technologies through Reagents /Instruments business and CDMO business and have promoted initiatives aimed at becoming a global platform
provider responsible for the infrastructure of the life science industry.
In the fiscal year under review, net sales decreased to ¥43,505 million (down 44.3% year-on-year) due to adecrease of sales of test-related products resulting from a change in the legal positioning of new Coronavirus
infectious disease, and a slump in the life science research market affected by the economic sluggishness overseas.
Cost of sales decreased to ¥16,597 million (down 50.3% year-on-year) due mainly to a decrease in sales. As aresult, gross profit decreased to ¥26,908 million (down 39.9% year-on-year). Selling, general and administrative(SG&A) expenses were ¥23,905 million (down 1.3% year-on-year) due to an increase in research and development(R&D) expenses and other expenses, and operating profit was ¥3,003 million (down 85.4% year-on-year).
As a result of the decrease in operating profit, ordinary profit decreased by ¥3,405 million (down 83.5% year-onyear), profit before income taxes and others was ¥2,853 million (down 86.6% year-on-year), and net income
attributable to owners of the parent was ¥1,480 million (down 90.8% year-on-year).
Since our group is a single segment, the disclosure by segment is omitted(2) Overview of Financial Position
Total assets at the end of the fiscal year under review were ¥121,252 million, a decrease of ¥7,949 million fromthe end of the previous fiscal year. This was mainly due to decreases of ¥16,430 million in cash and depositsand ¥1,156 million in accounts receivable-trade, despite increases of ¥8,119 million in property, plant andequipment and ¥2,020 million in other current assets.
Total liabilities at the end of the fiscal year under review were ¥9,467 million, a decrease of ¥7,280 million
from the end of the previous fiscal year. This was mainly due to decrease of ¥3,323 million in other current
liabilities, ¥2,486 in accrued payable-other, and ¥779 million in notes and accounts payable-trade.
Total net assets at the end of the fiscal year under review were ¥111,784 million, a decrease of ¥669 million
from the end of the previous fiscal year. This was mainly due to a decrease of ¥3,576 million in retained earnings,
despite an increase of ¥2,867 million in foreign currency translation adjustment due to the yen’s depreciation.
(3) Overview of Cash FlowsNet cash provided by operating activities amounted to ¥1,711 million, a decrease of ¥35,185 million from theprevious fiscal year. This was mainly due to depreciation and amortization of ¥4,279 million, income before
income taxes and others of ¥2,853 million, cash inflow from decrease in trade receivables of ¥1,501 million, adecrease in consumption taxes payable of ¥3,439 million, income taxes paid of ¥2,359 million, and a decreasein notes and accounts payable-trade of ¥928 million.
Net cash used in investing activities amounted to ¥13,043 million, an increase of ¥6,349 million from theprevious fiscal year. This was mainly due to proceeds from withdrawal of time deposits of ¥2,937 million,
purchase of property, plant and equipment and intangible assets of ¥12,778 million, and payments into time
deposits of ¥2,224 million.
Net cash used in financing activities totaled ¥5,233 million, mainly due to cash dividends paid of ¥5,052
million, an increase of ¥1,113 million compared with the previous fiscal year.
As a result of the above, the balance of cash and cash equivalents at the end of the fiscal year under review,
including the effect of exchange rate changes on cash and cash equivalents, decreased by ¥15,886 million fromthe end of the previous fiscal year to ¥33,171 million.

-2-(4) Future Outlook(Forecast of Net Sales)
In Reagent business, the life sciences industry's activities are declining worldwide due to economic conditions
and other factors. However, we expect sales of both Research/Catalog products and OEM/Custom-madeproducts to increase as we pursue a global, multipolar marketing/manufacturing/sales strategy. Specifically, inJapan, we will focus on application testing kits for private laboratories and other facilities, in the U.S. for OEM/custom-made products for LDT (laboratory developed test) such as the field of RHT (reproductive healthtechnology), and in Europe for OEM/Custom-made products related to genetic engineering. In China, we willdevelop new products for the Chinese market and respond to pricing. In Instruments business, we expect sales
to increase due to new products for next-generation single-cell analyzers, mainly in Japan and the United States.
In CDMO business, we expect an increase in revenues from contracted production of vector and mRNA,
contracted quality tests as contract services related to regenerative medicine products, using the second buildingof the Center for Gene and Cell Processing, which we have been investing in ahead of time. We also expect anincrease in revenues from contract services related to gene analysis/testing, as well as an increase in revenues
from new menus of proteome analysis, single-cell analysis, and spatial analysis.
In Gene Therapy business, we anticipate an increase in sales of AM products (ancillary materials for
manufacturing) such as mRNA related enzymes. Consequently, we anticipate an increase in sales in all categories.
Regarding the projected progress in consolidated net sales, we expect the first half to be approximately 41% of
the full year and the second half to be 59% of the full year.
In particular, there is a large bias in CDMO business, and we expect approximately 25% in the first half ofthe fiscal year and approximately 75% in the second half of the fiscal year.
(Forecast of Consolidated Financial Results)
For the full year ending March 31, 2025, we forecast a year-on-year increase in both sales and profits, with net
sales of ¥48,900 million, operating profit of ¥5,000 million, ordinary profit of ¥5,200 million, and net income
attributable to owners of the parent of ¥3,400 million.
For the cumulative second quarter, we forecast a year-on-year increase in sales but a decrease in profits, with
net sales of ¥20,200 million, operating profit of ¥150 million, ordinary profit of ¥250 million, and net income
attributable to owners of the parent of ¥100 million. As mentioned above, due to a bias in the progress of net
sales, we expect the progress of our operating profit forecast to be approximately 3% for the full year in the firsthalf of the fiscal year (we expect an operating loss in the first quarter) and 97% for the second half of the fiscal
year.
For a comparison between the forecasts for the following fiscal year and the results for the fiscal year ended
March 31, 2024, please refer "4. Supplementary Information (3) Comparative Statement of Profit and Loss
Statements Relating to Forecasts" on page 14 and later.

2. Basic Concept on Selection of Accounting Standards
The Group prepares its consolidated financial statements in accordance with Japanese GAAP, considering thecomparability of consolidated financial statements between periods and between companies.
With regard to the application of IFRS, the Company's policy is to respond appropriately, taking into accountvarious domestic and overseas circumstances.

-3-3. Consolidated Financial Statements and Primary Notes(1) Consolidated Balance Sheets(Millions of yen)
As of Mar. 31, 2023

AssetsCurrent assets
Cash and deposits
Notes receivable-trade
Electronically recorded monetary claimsoperating
Accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles,net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
Land
Leased assets
Accumulated depreciation
Leased assets, net
Construction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Technology-based intangible assets
Other
Total intangible assets
Investments and other assets
Deferred tax assets
Retirement benefit assets
OthersTotal investments and other assets
Total non-current assets
Total assets-4-

As of Mar. 31, 2024

51,847244

35,416
33

984

1,143

11,338
6,248
1,125
3,714
2,184
(118)
77,56910,181
6,784
970
4,096
4,205
(72)
62,75928,098(7,064)
21,0348,384(4,883)3,500

28,521(8,318)20,203
8,346(5,309)10,569(6,229)
4,340
8,654
756
(178)
578
2,102
992
(246)
745
40,956

11,673(7,674)
3,998
8,869
756
(231)
525
11,712
1,326
(597)
728
49,075

6,674
1,011
1,360
9,047

6,488
219
1,319
8,027

1,067
93
466
1,627
51,632
129,202

833
102
454
1,389
58,492
121,252

3,037

(Millions of yen)
As of Mar. 31, 2023
Liabilities
Current liabilities
Notes and accounts payable-trade
Lease obligations
Accrued payable-otherAccrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Lease obligations
Deferred tax liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Cumulative remeasurements of retirement
benefit
Total accumulated other comprehensive
incomeNon-controlling interests
Total net assets
Total liabilities and net assets-5-

As of Mar. 31, 2024

2,323
151
4,405
672
1,065
5,756
14,375

1,543
180
1,919
128
962
2,433
7,168

821
179
992
378
2,372
16,747

788
0
1,102
407
2,299
9,467

14,96532,89357,047104,906

14,96532,89353,471
101,330

7,680

10,548

(367)

(373)

7,312

10,174

235
112,454
129,202279
111,784
121,252

(2) Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income(Consolidated Statements of Profit or Loss)Year ended
Mar. 31, 2023

Net sales
Cost of sales
Gross profit
SG&A expenses
Provision for doubtful accounts
Employees' salaries and bonuses
Provision for accrued bonuses
Retirement benefit expenses
R&D expenses
Other
Total SG&A expenses
Operating profit
Non-operating income
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange loss
Rent expenses on real estate
Other
Total non-operating expenses
Ordinary profit
Extraordinary gains
Gain on sale of fixed assets
Insurance received
Total extraordinary profit
Extraordinary losses
Loss on disposal of fixed assets
Impairment loss
OthersTotal extraordinary losses
Profit before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent-6-78,14233,37744,765(Millions of yen)
Year ended
Mar. 31, 2024
43,505
16,597
26,908

79
5,877
574
249
8,575
8,865
24,224
20,541

(34)
6,192
454
305
8,324
8,663
23,905
3,003

142
158
62
363

186
97
165
64
513

24
120
70
6
221
20,682

23
74
12
111
3,405

251
678
930

3
3

348
39
388
21,224
4,679
496
5,176
16,04735
16,012

347
207
554
2,853
1,292
50
1,343
1,510
29
1,480

(Consolidated Statements of Comprehensive Income)Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest

Year ended
March 31, 2023

-7-

16,047(Millions of yen)
Year ended
March 31, 2024
1,510

4,478
(163)
4,315
20,363

2,882
(5)
2,877
4,387

20,319
43

4,343
44

(3) Consolidated Statements of Changes in Net Assets
Previous fiscal year (from April 1, 2022 to March 31, 2023)(Millions of yen)
Shareholders' equity

NonTotal
Cumulative
accumulated Controlling
remeasurements
Interestotherof retirement
comprehensive
benefitincomeTotal
net assets

Retainedearnings

Total
shareholders'equityForeigncurrencytranslation
adjustment

14,965 32,893 45,009

92,8683,208(3,973)(3,973)(3,973)16,012

16,012

16,012

Share
CapitalBalance at the
beginning of current
periodChange of items during
the period
Dividends fromsurplus
Net income
attributable to ownersof the parent
Net changes of items
other thanshareholders' equity
Total changes of items
during the period
Balance at the end ofcurrent period

Accumulated other comprehensive income

Capitalsurplus

-

(204)

3,004

191

96,064

4,471

(163)

4,307

43

4,351

- 12,038

12,038

4,471

(163)

4,307

43

16,38914,965 32,893 57,047

104,906

7,680

(367)

7,312

235

112,454

Current fiscal year (from April 1, 2023 to March 31, 2024)(Millions of yen)
Shareholders' equity

NonTotal
Cumulative
accumulated controlling
remeasurementsinterests
otherof retirement
comprehensive
benefitincomeTotal
net assets

Retainedearnings

Total
shareholders'equityForeigncurrencytranslation
adjustment

14,965 32,893 57,047

104,906

7,680(5,057)(5,057)(5,057)

1,480

1,480

1,480

Share
CapitalBalance at the
beginning of current
periodChanges of items during
the period
Dividends fromsurplus
Net income
attributable to ownersof the parent
Net changes of items
other thanshareholders’ equity
Total changes of items
during the period
Balance at the end ofcurrent period

Accumulated other comprehensive income

Capitalsurplus

-

(367)

7,312

235

112,454

2,867

(5)

2,862

44

2,906

- (3,576)(3,576)

2,867

(5)

2,862

44

(669)

14,965 32,893 53,471

101,330

10,548(373)

10,174279

111,784-8-

(4) Consolidated Statements of Cash Flows(Millions of yen)

Year ended

Year ended

Mar. 31, 2023

Net cash provided by (used in) operating activities
Income before income taxes and others
Depreciation and amortization
Impairment loss
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful
accounts
Increase (decrease) in reserve for bonuses
Increase (decrease) in retirement benefit
liabilities
Interest income
Interest expenses
Insurance claim income
Loss (gain) on sale and retirement of fixed assets

Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in notes and accounts
payable-trade
Increase (decrease) in consumption taxes
payableIncrease (decrease) in other current liabilities
OthersSubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Proceeds from insurance income
Subsidies received
Net cash provided by (used in) operating
activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant andequipment and intangible assets
Purchase of other depreciable assets
Subsidies received
Subsidy refund
OthersNet cash provided by (used in) investing
activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing
activities
Effect of exchange rate change on cash and cash
equivalents
Net increase (decrease) in cash and cash
equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period-9-Mar. 31, 2024
21,224
4,050
86
599

2,853
4,279
207
102
640

56

(53)

78

(144)

202

107

(142)
24
(678)
97
5,718
13,510

(186)
23
344
1,501
(324)

139

(928)

2,271

(3,439)(1,371)
162
46,028116(24)(9,902)
678
-

(508)
(114)
4,361
166
(22)
(2,359)(433)

36,897

1,711(17,769)
16,554(2,224)
2,937(5,747)(12,778)

396

9

(135)
7

(94)
462
(1,335)(19)(6,693)(13,043)(3,968)(151)(5,052)(181)(4,119)(5,233)813

678

26,897(15,886)

22,16049,05849,05833,171

(5) Notes to Consolidated Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Significant Accounting Estimates)(Goodwill)
Our group recorded goodwill at Takara Bio USA, Inc., which was recorded in the past upon the acquisition of
all of the shares of Clontech Laboratories, Inc., Rubicon Genomics, Inc. and WaferGen Bio-systems, Inc.,
respectively.
(1) Amounts recorded in the consolidated financial statements for the current fiscal year
(Millions of yen)
Fiscal Year under Review

Previous Fiscal Year
6,674

Goodwill

6,488(2) Information on the content of critical accounting estimates for identified items
The Group determined Takara Bio USA, Inc. as a reporting unit, including goodwill, and took procedures to
identify an indication of impairment. The recoverable amount of the reporting unit is based on its fair value.
Fair value is determined primarily based on the discounted present value of estimated future cash flows, which
utilize assumptions such as future growth rates to estimate such cash flows.
As the recoverable amount sufficiently exceeds the carrying amount at the end of the fiscal year under review,
the Company considers that it is unlikely that a material impairment loss will occur even if there is a reasonable
range of changes in future growth rates and other factors used in the calculation of the recoverable amount.
(Changes in Presentation Method)(Consolidated Statements of Cash Flows)"Increase (decrease) in consumption taxes payable," which was included in "Increase (decrease) in other current
liabilities" in cash flows from operating activities in the previous fiscal year, has been presented separately fromthe current fiscal year due to an increase in its monetary materiality. To reflect this change in presentation, theconsolidated financial statements for the previous fiscal year have been reclassified.
Consequently, ¥899 million, which was presented as "Increase (decrease) in other current liabilities" in cash
flows from operating activities in the Consolidated Statements of Cash Flows for the previous fiscal year, hasbeen reclassified as "Increase (decrease) in consumption taxes payable" of ¥2,271 million and "Increase(decrease) in other current liabilities" of minus ¥1,371 million.
(Segment Information)
Since our group is a single segment, this information is omitted.
(Per-Share Information)

Previous Fiscal Year
Fiscal Year under Review(From April 1, 2022 to March 31, 2023) (From April 1, 2023 to March 31, 2024)
Net assets per share¥931.93¥926.00
Net income per share¥132.97¥12.30(NOTE) 1. Diluted net income per share is not presented because there were no dilutive shares.
2. The basis for calculating net income per share is as follows.

- 10 -

Net income per share
Profit attributable to owners ofparent (Millions of yen)Amounts not attributable tocommon stock (Millions of yen)
Profit attributable to owners ofparent attributable to common
stock (Millions of yen)
Average number of shares ofcommon stock outstanding
during the period (Thousands ofshares)Previous Fiscal Year

Fiscal Year under Review(From April 1, 2022 to March 31, 2023)(From April 1, 2023 to March 31, 2024)

16,012

1,480

-

-

16,012

1,480

120,415

120,415(Significant Subsequent Events)
Not applicable.

- 11 -

4. Supplementary Information(1)Trends in Key Indicators for Business Management
1) Cash Flows(Millions of yen)Previous Fiscal Year
(Apr. 1, 2022 – Mar. 31, 2023)
Cash flow from operating
activities
Cash flow from investing
activities
Cash flow from financing
activities

Fiscal Year under Review(Apr. 1, 2023 – Mar. 31, 2024)

36,897

1,711(6,693)(13,043)(4,119)(5,233)2) Sales Breakdown by Region(Millions of yen)Previous Fiscal Year
(Apr. 1, 2022 – Mar. 31, 2023)

Japan
United States
China
Asia excluding Japan and
China
EuropeOthersTotal- 12 -

Fiscal Year under Review(Apr. 1, 2023 – Mar. 31, 2024)

45,667
12,886
10,79915,434
12,974
7,039

3,546

3,355

4,949
293
78,142

4,496
205
43,505

(2) Comparative Consolidated Statement of Income
Year ended
Mar. 31,2023(Net sales)
Reagents
Instruments
CDMO
Gene Therapy
Total net sales(Operating profit and Loss)(Rounded down to one million yen)
Year ended
Y/Y
Y/Y
Mar. 31,
ChangeRatio
2024

65,925
1,375
8,200
2,640
78,142

31,961
892
7,997
2,653
43,505(33,963)
(482)
(202)
12
(34,636)(51.5%)(35.1%)(2.5%)
0.5%(44.3%)

Operating profit

78,14233,37744,76524,224
653
48
699
8,575
13,790456
20,541

43,505
16,597
26,90823,905
571
72
676
8,324
13,955
304
3,003(34,636)(16,779)(17,856)
(318)
(81)
24
(23)
(251)
164
(152)
(17,537)(44.3%)(50.3%)(39.9%)(1.3%)(12.4%)
49.9%(3.3%)(2.9%)
1.2%(33.4%)(85.4%)

Ordinary profit

363
221
20,682

513
111
3,405

150
(110)
(17,277)41.5%(49.7%)(83.5%)

930
388
21,224
5,176
16,047

3
554
2,853
1,343
1,510

(927)
165
(18,370)(3,832)(14,537)(99.6%)
42.7%(86.6%)(74.0%)(90.6%)

35

29

(6)

(18.1%)

16,012

1,480(14,531)(90.8%)

4,050

4,279

229

5.7%

599

640

41

6.9%

Net sales

Cost of sales
Gross profit
SG & A expenses
Transportation expenses
Advertising expenses
Promotion expenses
R&D expenses
Administrative expense, other
Enterprise taxes (external standards taxation)(Non-operating income and Expenses)
Non-operating income
Non-operating expenses(Extraordinary gains & Losses)
Extraordinary gains
Extraordinary losses
Income before income taxes and others
Income taxes
Net income
Net income (loss) attributable to noncontrolling interests

Net income attributable to owners of
the parent
Depreciation and amortization(Property, plant and equipment andintangible assets)
Amortization of goodwill- 13 -

(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts(i) Consolidated Financial Results for the Six Months(Rounded down to one million yen)Six months ended
Six months ending
Y/Y Change
Y/Y Ratio
Sep. 30, 2024 Forecast
Sep. 30, 2023
(Net sales)
Reagents
14,703
15,503799
5.4%
Instruments
411
586
174
42.4%
CDMO
2,702
2,448
(254)
(9.4%)
Gene Therapy
1,298
1,661
363
28.0%
Total Net Sales
19,116
20,2001,083
5.7%(Operating profit and Loss)
19,116
20,2001,083
5.7%
Net sales
Cost of sales
5,772
7,900
2,127
36.9%
Gross profit
13,343
12,299(1,044)(7.8%)
SG & A expenses
11,933
12,149215
1.8%Transportation expenses
285
281
(3)
(1.1%)
Advertising expenses
32
42
9
29.6%
Promotion expenses
347
408
60
17.5%
R&D expenses
4,241
3,567
(673)
(15.9%)
Administrative expenses,
6,872
7,678
805
11.7%
other
Enterprise taxes(external standards
154
170
16
10.5%
taxation)
1,410
150(1,260)(89.4%)
Operating profit(Non-operating income andExpenses)Non-operating income
248
176
(71)
(28.8%)
Non-operating expenses
59
76
16
28.4%
1,598
250
(1,348)(84.4%)
Ordinary profit(Extraordinary gains &Losses)Extraordinary gains
1(1)
Extraordinary losses
12
15
3
27.5%
Income before income
1,588
234
(1,354)(85.3%)
taxes and others
Income taxes
489
111
(378)
(77.3%)Net income
1,099
123
(976)
(88.8%)Net income (loss)
attributable to non14
23
8
54.5%
controlling interests

Net income
attributable toowners of parent

Depreciation andamortization (Property,
plant and equipment andintangible assets)
Amortization of goodwill

1,084

100

(984)

(90.8%)

2,132

1,848

(283)

(13.3%)

307

318

11

3.7%

* From the fiscal year ended March 31, 2024, we began adding sales of mRNA manufacturing related products forresearch use, which had been included in "Reagents" until the fiscal year ended March 31, 2023, to "Gene Therapy."
The results for the year ended March 31, 2024 in this table have been reclassified to reflect this change.

- 14 -

(ii) Consolidated Financial Results for the Full Year

(Rounded down to one million yen)

Year ended
Mar. 31, 2024

Year ending
Mar. 31, 2025 Forecast

Y/Y Change

31,405
892
7,997
3,209
43,50533,9691,520
10,0003,410
48,900

2,563
627
2,002
201
5,394

8.2%
70.3%
25.0%
6.3%
12.4%

43,505
16,597
26,90823,905
571
72
676
8,324

48,90019,301
29,59824,598
621
85
878
7,200

5,394
2,704
2,690
693
49
12
202
(1,124)

12.4%
16.3%
10.0%
2.9%
8.6%
17.0%
29.9%
(13.5%)

13,955

15,467

1,512

10.8%

304

345

41

13.7%

Operating profit

3,003

5,000

1,996

66.5%

Ordinary profit

513
111
3,405

355
155
5,200

(157)
44
1,794

(30.7%)
39.8%
52.7%

3
554

51

(3)
(503)

(90.7%)

2,853

5,148

2,294

80.4%

1,343
1,510

1,707
3,440

363
1,930

27.1%
127.8%

29

40

11

39.3%

1,480

3,400

1,919

129.6%

4,279

3,710

(569)

(13.3%)

640

637

(3)

(0.5%)(Net sales)
Reagents
Instruments
CDMO
Gene Therapy
Total Net Sales(Operating profit and Loss)

Net sales

Cost of sales
Gross profit
SG & A expenses
Transportation expenses
Advertising expenses
Promotion expenses
R&D expenses
Administrative expenses,
otherEnterprise taxes(external standards
taxation)(Non-operating income andExpenses)Non-operating income
Non-operating expenses(Extraordinary gains &Losses)Extraordinary gains
Extraordinary losses
Income before income
taxes and others
Income taxes
Net income
Net income (loss)
attributable to noncontrolling interests

Net income
attributable toowners of parent

Depreciation andamortization (Property,
plant and equipment andintangible assets)
Amortization of goodwill

Y/Y Ratio* From the fiscal year ended March 31, 2024, we began adding sales of mRNA manufacturing related products for researchuse, which had been included in "Reagents" until the fiscal year ended March 31, 2023, to "Gene Therapy." The results
for the year ended March 31, 2024 in this table have been reclassified to reflect this change.

- 15 -